Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
(Bezafibrate + obeticholic acid) by Intercept Pharmaceuticals for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
(Bezafibrate + obeticholic acid) is under clinical development by Intercept Pharmaceuticals and currently in Phase III for Primary Biliary Cholangitis...